The rise in atmospheric carbon dioxide concentration, and its potentially catastrophic effect on global climate, is one of the most significant challenges in developing a secure energy future in the 21st Century. Solving this problem requires a concerted technological effort directed at amelioration of extant CO 2 emission sources, a reduction of current levels of atmospheric greenhouse gases, and increased utilization of greener approaches for future energy needs (such as solar, 1 wind, 2 geothermal, 3 etc.). The ability to successfully capture carbon dioxide is a crucial component in achieving all of these goals, but recent estimates 4 indicate that current carbon sequestration approaches will likely prove to be costlier than once thought. Moreover, the most common industrial method used to capture CO 2 involves reacting the gas with monoethanolamine, which can cause machinery corrosion and results in hazardous chemical waste byproducts. 5 Environmentally friendly carbon capture techniques may be found in the biosphere, as 10 11 tons of CO 2 are sequestered annually by the enzyme RuBisCO, 6 which catalyzes the carboxylation of ribulose-1,5-bisphosphate in the Calvin cycle. RuBisCO is estimated to be the most abundant protein on Earth; 6 unfortunately, its poor catalytic efficiency 7 (k cat ≈ 1-10 s -1
) makes it an unlikely starting point for protein-based carbon capture approaches. Previous biomimetic efforts 8, 9 have instead utilized the enzyme carbonic anhydrase, which can catalyze on the order of one million CO 2 hydration reactions per second; 10 concerns, however, exist about enzymatic poisoning 8 and stability. 9 Thus, it is beneficial to identify alternative protein-based mechanisms to trap CO 2 , which fundamentally requires an accurate description of protein-CO 2 interactions at atomic (i.e., primary sequence) resolution. Using a combined bioinformatics and molecular modeling approach, we have previously described 11 some common trends among the roughly 20 crystallographically characterized protein-CO 2 complexes (Table 1) found in the Protein Data Bank (PDB). 12 However, these few experimentally obtained crystal structures are only a small fraction of the ∼60 000 macromolecules contained in the PDB. Therefore, efficient discovery of novel protein-based CO 2 sequestration systems depends on in silico approaches.
Although computational methods for a priori detection of the ligand binding site (or the active site) within a protein have been previously proposed, with obvious emphasis on drug discovery, CO 2 as a ligand presents some unique challenges that may be difficult for standard approaches to overcome. First, carbon dioxide possesses very limited functionality, and so techniques that rely on chemically diverse ligands to predict a *To whom correspondence should be addressed. E-mail: drummondml@ gmail.com.
( binding site will likely be ineffective.
13,14 Also, because of the small size of CO 2 , methods incorporating a coarse-grained representation of amino acids 15,16 will generally not possess the resolution necessary to reveal all important protein-carbon dioxide interactions, as has been noted previously. 17 Another consequence of its small size is the fact that CO 2 does not require a traditional deep pocket, cavity, or cleft to bind, and so the existence of these entities should not be presumed. 18 Instead, CO 2 binding sites are small and localized, spanning perhaps several residues rather than several dozen, and thus predictions should be parsimonious.
19-21 Moreover, because CO 2 is known to bind allosterically (in, e.g., hemoglobin 22 or adenylyl cyclases 23 ), the utility of approaches developed exclusively for locating enzyme active sites is uncertain.
24,25 Finally, given the enzymatic variety shown in Table 1 , predictions based on evolutionary similarity, sequence homology, or characteristic, large-scale differences between binding and nonbinding sites may encounter significant obstacles. [26] [27] [28] To address these difficulties, we have utilized the pharmacophore concept, which was developed for use in drug discovery. 29 A pharmacophore is the geometric arrangement of a drug's functional groups (such as aromatic ring centers or hydrogen bond donors) that are thought to be responsible for the drug's potency. Critically, a pharmacophore is inherently three-dimensional, generally consisting of distance, angle, and torsional ranges between functional groups. It has recently been shown 30 that geometric features taken from 3D protein coordinates (as determined by X-ray crystallography) are able to predict ice-binding sites; as will be shown below, CO 2 -binding sites can similarly be elucidated.
The biggest difference between the traditional use of the pharmacophore in drug discovery and the approach used in this work is that, in the former case, the pharmacophore describes the functional group geometry of a ligand, whereas herein the ligand of interest is always carbon dioxide and thus we seek instead to describe protein geometries (i.e., predicted CO 2 binding sites) by using the pharmacophore concept. In some respects, the work detailed below represents a refinement of the recently developed structure-based (or receptorbased) pharmacophore methodology, [31] [32] [33] [34] [35] which uses the structural features of a specific protein to guide database mining efforts to locate appropriately complementary ligands. However, in the current work, the database mining efforts will locate proteins that are appropriately complementary to the specific CO 2 ligand, thus enabling the prediction of new CO 2 binding sites that have not yet been revealed through protein crystallography.
The procedure to reveal these new binding sites begins by first extracting the coordinates of specific functional group arrangements (i.e., hydrogen bond donors [e.g., the -NH 2 amine groups of Arg or the -OH hydroxyl group of Ser] and hydrogen bond acceptors, as well as aromatic ring centers) near CO 2 in the crystallographically known protein-CO 2 structures ( Table 1 ). The next step involves translating these features into a pharmacophoric query (see Methods section) suitable for database mining. Finally, these queries are applied to a test set of enzymes that have crystallographically determined structures but do not yet have similarly established protein-carbon dioxide structures. The database mining procedure therefore reveals the presence of functional group arrangements known to be able to ligate CO 2 in a new set of enzymes.
The enzyme in our test set is phosphoenolpyruvate carboxykinase (PEPCK), which catalyzes the reversible carboxylation and dephosphorylation of phosphoenolpyruvate to form oxaloacetate. PEPCK is known from kinetic isotope studies 36 to possess a distinct carbon dioxide binding site. In fact, three of the known protein-CO 2 complexes in Table 1 are PEPCKs. The test set consists of the additional 18 PEPCK crystal structures in the PDB (see Supporting Information) that do not possess a bound CO 2 . When the pharmacophorebased approach is applied to search this test set, reasonable and specific CO 2 -binding sites are generated in silico for most of these 18 enzymes. After presenting the query construction and database mining results, a discussion of the validity and significance of these findings is offered, followed by a detailed description of the methods used.
Results
Using the selection criteria and the procedure described in the Methods section, pharmacophore queries were created from the local functional group environments of bound carbon dioxide in 13 of the 22 protein-CO 2 complexes listed in Table 1 . Details of these queries are given in Table 2 , along with results from searching the 18-member PEPCK test set for potential CO 2 binding sites using these queries. As can be seen, regardless of how protein-bound water molecules are treated (see Methods for details), the number of pharmacophoric features included in a query greatly influences the number of proposed binding sites. For example, the least stringent query is the one constructed from the protein-CO 2 crystal structure of 2VBK, 37 which yields a hit when it matches a three-dimensional arrangement comprised of four functional groups; over 3500 examples of this functional group arrangement are found throughout the PEPCK test set, which corresponds to an average of almost 200 proposed CO 2 binding sites per PEPCK enzyme. Interestingly, for pharmacophores in the drug discovery field, four features is widely held 29 as the upper limit to allow for useful pattern recognition; the different behavior in this study is clearly a reflection of the increased size and functional group density of the protein database compared to the small molecule databases generally studied with traditional pharmacophores.
In mining the PEPCK test set, aromatic ring centers, although known to be used by proteins to bind CO 2 , 38 lead to queries that generally fail to predict new binding sites. The vast majority of the hits in Table 2 , therefore, are matched patterns of hydrogen-bond donors and acceptors. The sole exception is in the case of the 2I61-based query; however, without the inclusion of the ring center, this query would possess only four features and would therefore likely lead to thousands of predicted CO 2 binding sites, as in the case of the four-featured 2VBK query. Similarly, removing all water molecules from both the generated queries and the PEPCK test set ( Table 2 , dry proteins; refer to Methods section for details) increases the specificity of the database mining procedure.
A typical predicted binding site is shown in Figure 1 , where the six functional groups used to bind CO 2 in the crystal structure 39 of 1KEK are shown to overlap with an analogous functional group arrangement located within the active site (AS) cleft of the test set PEPCK 1YTM. 40 A few points should be made about this prediction. First, our approach does not discriminate between side chain and backbone functional groups, as demonstrated by query element (4), where the need for an appropriately positioned hydrogen-bond donor is fulfilled by a side chain nitrogen of Arg114 in the known CO 2 binding site in 1KEK, but by the backbone nitrogen of Ser1355 in the proposed binding site in 1YTM. As a result, residues without a functionalized side chain can contribute toward CO 2 binding, as in the case of Leu1354 in 1YTM. Second, multiple functional groups from the same amino acid residue can help to bind CO 2 if they are positioned correctly, as in the case of the side chain OH and both the backbone O and N-H of Thr31 in 1KEK. This occurrence cannot be predicted with previous in silico methods that rely on a coarse-grained amino acid respresentation.
15,16 Third, nonamino acid moieties are predicted to be able to contribute directly to the CO 2 binding environment, as in the case of water in 1YTM and 2-acetyl thiamine diphosphate (AcThDP) in 1KEK. Finally, pharmacophoric functional groups need not be part of a continuous amino acid chain, as seen by the contributions to the CO 2 binding site of Thr31 and Asn996 in 1KEK. Indeed, while not depicted in Figure 1 , binding sites predicted with the current pharmacophore-based method can incorporate functional groups located on different protein chains, which is necessary to detect binding sites found at the junction of two or more protein domains. Two of the queries listed in Table 2 proved to be especially effective at locating putative CO 2 binding sites within the AS clefts of the PEPCK test set: the 1KEK-based query incorporating certain water molecules (see Methods) and the "dry" 2OLQ-based query (where water molecules were stripped away entirely). Results for these two approaches are given in Table 3 , as are calculated hydropathy indices (HI) 41 and normalized temperature factors. 42 The first of these properties gauges the tendency for a short protein segment to assume a transmembrane coil topology; HI therefore serves as an estimate of the local hydrophobic character of a predicted binding site, where sites with greater hydrophilicity have larger values. B norm , the second property listed in Table 3 , allows for a comparison across different proteins of the degree of thermal motion exhibited by the functional groups identified by the pharmacophoric query. As can be seen in Table 3 , 1KEK-derived CO 2 binding sites located in the PEPCK AS cleft have greater (less negative) hydropathy indices than do the predicted binding sites located outside of the AS cleft. For the binding sites predicted using the 2OLQ-based query, those located within the AS cleft generally have lower B norm values, indicating less thermal motion compared to those sites predicted to exist outside of the AS cleft. The potential use of these two parameters will be discussed below.
Discussion
Both of the database mining efforts detailed in Table 3 predict multiple CO 2 binding sites for many of the PEPCK test set enzymes (e.g., for 2QEW, three sites were predicted using wet-1KEK [ Figure 2a ] and one using dry-2OLQ [ Figure 2b] ). Moreover, for a given enzyme, the two procedures in Table 3 yield predicted CO 2 binding sites that, while often located near one another, are never precisely colocated (cf. the predicted binding sites in Figure 2c and 2f) . The obvious question, therefore, is which predictions are legitimate CO 2 binding sites and which are false positives? More generally, how many CO 2 binding sites can a protein be expected to possess?
Previous theoretical investigations using molecular dynamics [45] [46] [47] have predicted up to three carbon dioxide binding sites in human carbonic anhydrase II. In addition, five of the crystallographically characterized protein-CO 2 complexes in Table 1 (2BGI,  48 2OLR,  43 2VBK,  37 3D92,  38 and  3D93   38 ) show two bound carbon dioxides per asymmetric unit. We have previously calculated, 11 using the ab initio composite method ccCA 49 (which exhibits an average deviation from experiment of ≈1-2 kcal/mol for a number of varied systems [50] [51] [52] [53] and thus can serve as an accurate approximation to missing experimental data), interaction energies between a CO 2 molecule and water, ammonia, and benzene, which serve as simple models for the pharmacophoric features employed in the current study. Although these calculated binding energies are small (-2.1, -2.1, and -1.3 kcal/mol, respectively), which would suggest loose binding, mobile CO 2 ligands, and thus numerous binding sites within a protein, the CO 2 -arginine interaction energy calculated with ccCA is -6.1 kcal/mol, indicating that protein-CO 2 interactions are additive and perhaps even synergistic. It is therefore conceivable that the sites predicted by the six-feature queries of Table 3 bind CO 2 with an appreciable binding energy of >10 kcal/mol. Thus, irrespective of the total number of loosebinding CO 2 pockets a protein may possess, the predictions in Table 3 may be considered as perhaps the tightest CO 2 binding pockets found among a set of multiple, less-effective binding sites. Efforts are currently underway to develop a scoring function capable of efficiently and accurately calculating the interaction energy (including water molecules) for each predicted site, with the goal of ranking the affinity (and therefore likely relevance) of multiple CO 2 binding site predictions. Experimentally, site-specific mutagenesis studies will also be of great importance for validating predicted binding sites.
From the current data, insight about the potential relevance of binding site predictions can be gained from the evaluated properties listed in Table 3 . For example, the 1KEK-based query predicted three CO 2 binding sites for the PEPCK 2QEW (Figure 2 ). The site with the highest hydropathy index (Table 3) is deep within the AS cleft (Figure 2c) . Thus, using this query, a CO 2 binding site for an enzyme of unknown function (such as might result from a structural genomics study 54 ) with a similarly high HI might also be expected to play Figure 1 . Overlay of the known CO 2 binding site from the crystal structure 39 of 1KEK (red) and the CO 2 binding site predicted using the approach of this work for the unliganded PEPCK 1YTM 40 (green). Hydrogen atoms have been omitted for clarity, as have all protein residues not flagged by the 1KEK query. The position of CO 2 (known for 1KEK, predicted for 1YTM) is shown in gray using the van der Waals radii of carbon and oxygen. AcThDP is the 2-acetyl-thiamine diphosphate ligand found in 1KEK (labeled HTL in the PDB), of which only the 2-acetyl-thiazole moiety is shown, for the sake of clarity. For the query types, "D" is a hydrogen-bond donor, "A" is a hydrogen-bond acceptor, and "D&A" must be both a hydrogen-bond donor and acceptor. a role in AS catalysis. Site (d) in Figure 2 is at the entrance to the AS cleft, and its HI is somewhat lower than that calculated for site (c). Site (e) is located outside of the AS cleft and accordingly has a very negative hydropathy index. Previous theoretical work on human carbonic anhydrase II has similarly predicted multiple CO 2 binding sites located at varying distances from the AS; these sites were suggested to serve as secondary CO 2 recognition/binding sites 45 or as steps in a CO 2 relay. 46 It is also feasible that a site such as (e) might serve as an allosteric binding site, 22, 23 although obviously further experimental and theoretical work is needed to investigate this possibility.
However, even if further study suggests that sites such as (d) and (e) do not play a role in capturing CO 2 but are instead false positives from the database mining procedure, it is striking that the three-dimensional pharmacophoric elements located in the oxidoreductase 1KEK (EC No. 1.2.7.1) are also commonly found in the AS clefts of the test set lyase PEPCK (EC No. 4.1.1.X). Not only do these enzymes catalyze entirely different reactions, there is essentially no (<2%) pairwise sequence identity between 1KEK and any PEPCK. Yet despite their dissimilarity, when the CO 2 -binding functional group arrangements are compared using the approach of this work, common patterns are repeatedly identified, in line with a previous hypothesis 55 that enzymes have evolved to use similar structural scaffolds to catalyze divergent reactions. In other words, the current work seems to have identified CO 2 binding motifs that are functional group specific rather than residue specific and are found across species and even across enzyme families. For example, the putative CO 2 binding site in the PEPCK 1YTM (from the bacterium A. succiniciproducens), which was identified by using the known CO 2 binding site pattern of the oxidoreductase 1KEK (from the bacterium D. africanus), is comprised of Thr-Leu-Ser-Arg (and water, see Figure 1) ; the binding motif of 1KEK also matches the arrangement Thr-Leu-Thr-Arg (Thr = methylated Ser) in the PEPCK 1OS1 (from the bacterium E. coli).
Similarly, the dry-2OLQ query, derived from the PEPCK of E. coli, matches a three-dimensional arrangement of Val335-Ala336-Asn403-Arg405 found in both 1M51, the PEPCK of humans, and in 2QEW, the PEPCK of rats, suggesting that this nonsequential arrangement is conserved across species because of its role in binding CO 2 . Perhaps most importantly, all of the predicted PEPCK CO 2 binding sites just mentioned are within the known AS clefts of their respective PEPCKs.
There are numerous potential applications of the pharmacophore-based CO 2 binding site prediction method described in this research. The conservation of structural motifs across species and enzyme families revealed by this work can serve as the basis for an approach complementary to traditional homology methodologies that investigate primary sequence similarity. Moreover, the pharmacophore-based framework can readily be modified to predict binding sites for very small catalytically important ligands other than CO 2 , such as metal cations, N 2 , O 2 , etc. These queries can rapidly be used for in silico structure-function predictions, to help determine the purpose of new proteins whose structures (but little else) are known using high-throughput X-ray crystallography techniques. 54 Because the CO 2 binding sites predicted herein are specific, spanning at most six amino acid residues, they may also be used to guide site-specific mutagenesis experiments designed to enhance CO 2 binding efficiency. 56 Finally, and perhaps of most immediate importance, the 3D protein structural arrangements identified in this work as crucial for binding carbon dioxide can be employed in biomimetic efforts to yield natural and novel next-generation CO 2 sequestration and utilization technologies.
Methods
The Molecular Operating Environment (MOE) program 57 was used for protein manipulation, pharmacophore generation, Table 1 were downloaded from the PDB 12 using their four-character accession codes. Only those structures possessing a roughly linear CO 2 (defined as possessing an OdCdO angle of >160°) were chosen for study, as smaller angles are indicative of a carbamate (or bicarbonate) group rather than a distinct, bound CO 2 ligand. Furthermore, there are two pairs of complexes in Table 1 that consist of identical proteins with different cofactors: 2OLQ 43 is the E. coli PEPCK holoenzyme whereas 2OLR 43 is the apoenzyme, and 3D92 38 is the holoenzyme of human carbonic anhydrase II whereas 3D93 38 is the apoenzyme. In both cases, only the holoenzyme forms were investigated.
For the remaining protein-CO 2 complexes in Table 1 , hydrogen atoms were added with MOE using the default settings. Residues within 4.5 Å of the bound carbon dioxide ligands were then selected and described based on their pharmacophoric character with respect to aromatic ring centers, hydrogenbond donors (O and N), and hydrogen-bond acceptors (N and O atoms bonded to at least one H), as defined by the PCH (polarity-charged-hydrophobicity) annotation scheme in MOE. 57 The crystal structure of 2VBK 37 shows two bound CO 2 molecules, but one of them (near Ala362) has only one PCH feature within 4.5 Å , and thus was deemed too vague to define a useful pharmacophoric query. The CO 2 near Phe226 in 3D92 38 also has only one PCH feature within a 4.5 Å radius and was therefore similarly rejected.
To generate pharmacophoric queries from the environments around carbon dioxide in these protein-CO 2 complexes, a sphere of 0.75 Å radius was centered around each PCH feature listed above; the queried feature is considered to match a target if they overlap within the radius of this sphere, thereby allowing for a small degree of variability. Queries were also generated using spheres with radii of 0.6, 0.9, 1.0, and 1.1 Å , but results (not shown) indicated that 0.75 Å yielded the best balance between specificity and flexibility. Preliminary results also indicated that allowing for a partial match in the mining procedure (i.e., not all PCH features must be matched in the target database) gave too many hits to be useful. In all queries, the carbon and oxygen atoms of the bound CO 2 molecules were replaced with spheres of excluded volume, set to the elemental van der Waals radii, to prevent protein overlap with predicted binding sites.
The nature of the interaction of a carbon dioxide molecule with nearby water molecules at a molecular level is an area of active research. Recent high-level ab initio work 58 has concluded that at least three water molecules are needed to effect the hydration of CO 2 to form HCO 3 -, although the presence of a protein environment (as in the current study) will likely influence the pertinent reaction barriers. By restricting the protein-CO 2 complex data set (see above) to those with an OdCdO angle >160°, it is hoped that the species being investigated with the pharmacophore-based method is microsolvated 58 CO 2 rather than hydrated CO 2 (bicarbonate); this assumption has been verified experimentally in at least one case 43 via a kinetic assay. A more explicit study of the balance between CO 2 and HCO 3 -in proposed protein binding sites would require further, thorough theoretical investigations. Absent such work, we have chosen to address the participation of water within 4.5 Å of bound CO 2 in the known protein-CO 2 complexes in three ways.
In the first scenario, all crystallographically located water molecules were allowed to contribute to pharmacophoric queries; however, these models (results not shown) were generally too specific to make any predictions. In the second scenario, only relatively stationary water molecules were incorporated into the queries, as defined by B norm , the normalized temperature factor. 42 B norm is equal to (B -B Prot )/σ(B Prot ), where B is the experimental temperature factor of the atom in question, B Prot is the average temperature factor for all heavy protein atoms (excluding water, ligands, cofactors, etc.), and σ is the standard deviation. Queries built only with water molecules with a B norm less than 0.1 (i.e., only slightly more mobile than the protein itself) are referred to in the text as "wet." In the third scenario, no water molecules were allowed to contribute to the pharmacophoric descriptions; all queries generated under this constraint are labeled as "dry" in the text and were applied to a PEPCK test set where all water molecules had also been removed. The B norm values listed in Table 3 are averages of the normalized temperature factors for the six atoms flagged by the pharmacophoric queries.
The PEPCK test set database mined throughout this work consists of those enzymes in the PDB 12 flagged by searching for the keyword "PEPCK" that are not listed in Table 1 (i.e., that do not have an experimentally located CO 2 ). The PDB codes for these 18 enzymes are: 1II2, 1K3C, 1KHB, 1M51, 1NHX, 1OS1, 1YTM, 1YVY, 2FAF, 2GMV, 2PC9, 2PY7, 2QEW, 2QF1, 2QZY, 2RKA, 2ZCI, and 3DTB. References and further details for these enzymes are provided as Supporting Information. Mining this 18-member test set using MOE on a standard desktop PC generally takes around 30 s per pharmacophoric query.
The hydropathy index (HI) was calculated using Membrane Protein Explorer (MPEx), 41 version 2.2a. The octanol scale was used, scanning over a 19 amino acid window. The values in Table 3 are averages of all amino acid residues within 4.5 Å of the predicted CO 2 binding sites (i.e., not just those matched by the pharmacophoric query).
